Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The firm is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The firm seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The firm is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Follow-Up Questions
¿Quién es el CEO de Ernexa Therapeutics Inc?
Mr. Sanjeev Luther es el President de Ernexa Therapeutics Inc, se unió a la empresa desde 2024.
¿Qué tal es el rendimiento del precio de la acción ERNA?
El precio actual de ERNA es de $1.37, ha increased un 7.87% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Ernexa Therapeutics Inc?
Ernexa Therapeutics Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Ernexa Therapeutics Inc?
La capitalización bursátil actual de Ernexa Therapeutics Inc es $10.5M
